SCHEMBL5583274

SCHEMBL5583274

Clc1ccc2[nH]c3c(ccc4cn[nH]c43)c2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS1 P29475 3/20 0.51
DYRK1A Q13627 2/20 0.51
CHUK O15111 1/20 0.45
MAPK10 P53779 2/20 0.44
KDM4E B2RXH2 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
HSD17B10 Q99714 2/20 0.44
LMNA P02545 2/20 0.44
USP2 O75604 1/20 0.44
ALDH1A1 P00352 1/20 0.44
HSP90AA1 P07900 1/20 0.44
MAPT P10636 1/20 0.44
ALOX15 P16050 1/20 0.44
MAPK1 P28482 1/20 0.44
GFER P55789 1/20 0.44
RXFP1 Q9HBX9 1/20 0.41
MAT2A P31153 1/20 0.41
PIM3 Q86V86 1/20 0.39
METAP2 P50579 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5583287 0.82 PIM3 (0.60) NOS1DYRK1ACHUKLMNAMAPK1
SCHEMBL5583293 0.82 ACHE (0.46) MAPK10KDM4EMEN1KMT2AHSD17B10
SCHEMBL16433002 0.82 CHUK (0.52) CHUKMEN1KMT2AHSD17B10LMNA
SCHEMBL29538654 0.82 CHUK (0.52) CHUKMEN1KMT2AHSD17B10LMNA
SCHEMBL5582982 0.78 KDM4E (0.54) DYRK1ACHUKMAPK10KDM4EMEN1
SCHEMBL5583310 0.78 KIF11 (0.58) KDM4EMEN1KMT2AHSD17B10ALDH1A1
SCHEMBL5583175 0.74 PIM3 (0.47) MAPK10KDM4EMEN1KMT2AHSD17B10
SCHEMBL30394992 0.74 GABRP (0.55) CHUKKDM4EMEN1KMT2AHSD17B10
SCHEMBL16432834 0.74 GABRP (0.55) CHUKKDM4EMEN1KMT2AHSD17B10
SCHEMBL24032327 0.73 KIF11 (0.66) DYRK1ACHUKKDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070254877-A1 Indole Derivative and Use for Treatment of Cancer TAKADA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-11-01 US claimed
US-20070254877-A1 Indole Derivative and Use for Treatment of Cancer TAKADA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254877-A1 Indole Derivative and Use for Treatment of Cancer IGF1R, KDR, ERBB2 NOS1 332/4885DYRK1A 55/4885CHUK 92/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.